BioRestorative Therapies, Inc. (BRTX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BRTX Revenue Growth
Revenue Breakdown (FY 2024)
BRTX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
BRTX Revenue Analysis (2013–2024)
As of May 8, 2026, BioRestorative Therapies, Inc. (BRTX) generated trailing twelve-month (TTM) revenue of $383,400, reflecting significant decline in growth of -94.9% year-over-year. The most recent quarter (Q3 2025) recorded $11,800 in revenue, down 96.1% sequentially.
Looking at the longer-term picture, BRTX's 5-year compound annual growth rate (CAGR) stands at +25.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $628,915 in 2015.
Revenue diversification analysis shows BRTX's business is primarily driven by Product (75%), and Royalty (25%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MESO (+191.4% YoY), XTNT (+16.9% YoY), and MDXG (+10.5% YoY), BRTX has underperformed the peer group in terms of revenue growth. Compare BRTX vs MESO →
BRTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BRTXCurrent | $383,400 | -94.9% | +25.3% | -2881.6% | |
 MESO | $17M | +191.4% | -11.8% | -363.1% | |
 XTNT | $117M | +16.9% | +12.6% | -10.3% | |
 MDXG | $419M | +10.5% | +11.0% | 15.3% | |
 RGEN | $738M | +17.4% | +15.0% | 8.1% | |
 CYTK | $88M | +450.6% | +9.5% | -695.4% |
BRTX Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $401K | +175.0% | $373K | 93.0% | $-11,555,194 | -2881.6% |
| 2023 | $146K | +21.7% | $146K | 100.0% | $-15,220,774 | -10439.5% |
| 2022 | $120K | +160.4% | $120K | 100.0% | $-18,974,025 | -15838.1% |
| 2021 | $46K | -40.3% | $46K | 100.0% | $-26,307,873 | -57191.0% |
| 2020 | $77K | -40.8% | $77K | 100.0% | $-2,752,076 | -3574.1% |
| 2019 | $130K | +17.1% | $130K | 100.0% | $-8,432,005 | -6486.2% |
| 2018 | $111K | +37.0% | $111K | 100.0% | $-7,647,652 | -6889.8% |
| 2017 | $81K | +122.8% | $-178,260 | -220.1% | $-8,374,284 | -10338.6% |
| 2016 | $36K | -94.2% | $36K | 99.7% | $-7,797,257 | -21447.6% |
| 2015 | $629K | +51.2% | $367K | 58.4% | $-7,170,362 | -1140.1% |
See BRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BRTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BRTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBRTX — Frequently Asked Questions
Quick answers to the most common questions about buying BRTX stock.
Is BRTX's revenue growth accelerating or slowing?
BRTX revenue declined -94.9% year-over-year, contrasting with the 5-year CAGR of +25.3%. TTM revenue fell to $383400.00. This reverses the prior growth trend.
What is BRTX's long-term revenue growth rate?
BioRestorative Therapies, Inc.'s 5-year revenue CAGR of +25.3% reflects the variable expansion pattern. Current YoY growth of -94.9% is below this long-term average.
How is BRTX's revenue distributed by segment?
BRTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.